Trial Profile
A study of the resistance mechanism of EGFR-TKI in EGFR gene mutation positive non-small cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2020
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 05 Sep 2018 Status changed from not yet recruiting to recruiting.
- 05 Mar 2018 New trial record